뒤로
Rani Therapeutics Holdings Inc(RANI) 가격
RANI 주가 차트
RANI 수입
Rani Therapeutics Holdings Inc
$1.3
-2.61%
$-0.03
오늘 기준:Feb 11, 12:32:02 GMT-5
최신 수익 결과: Q3 '25
보고됨: 2025-11-06
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
RANI의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Rani Therapeutics Holdings Inc RANI의 지난 분기 매출 실적은 어땠나요?
Rani Therapeutics Holdings Inc의 매출 추정치는 얼마인가요?
Rani Therapeutics Holdings Inc의 수익 품질 점수는 얼마인가요?
Rani Therapeutics Holdings Inc는 언제 수익을 보고하나요?
Rani Therapeutics Holdings Inc의 예상 수익은 얼마인가요?
Rani Therapeutics Holdings Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$1.34
시가
$1.34
일일 범위
$1.3 - $1.34
52주 범위
$0.387 - $3.87
거래량
377.6K
평균 거래량
2.0M
EPS(TTM)
-0.79
배당수익률
--
시가총액
$158.5M
RANI란 무엇인가요?
Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company is headquartered in San Jose, California and currently employs 105 full-time employees. The company went IPO on 2021-07-30. The firm has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The company has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. The company is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).